The PANC-PALS consortium is committed to providing a platform where pancreatologists can collaborate, share their expertise, and advance patient care.
Honored to present PANC-PALS Collaborator-led consortium and global registry 💪🏻💪🏻
Thank you for everyone’s hard work to get IRBs and contracts signed 📈🧑💻
@ammaraj.bsky.social
Honored to present PANC-PALS Collaborator-led consortium and global registry 💪🏻💪🏻
Thank you for everyone’s hard work to get IRBs and contracts signed 📈🧑💻
@ammaraj.bsky.social
Great discussions followed by a drink by the East River 😎
#PANCPALS
@ammaraj.bsky.social
Great discussions followed by a drink by the East River 😎
#PANCPALS
@ammaraj.bsky.social
@ammaraj.bsky.social
@ammaraj.bsky.social
@pancan.bsky.social
@ammaraj.bsky.social
@pancan.bsky.social
@ammaraj.bsky.social
💉 Gemcitabine + S1 median OS 37 months vs. 26
💡 Is neoadjuvant chemo extending survival over upfront surgery?!
🤔 What are your thoughts?! 💭
journals.lww.com/annalsofsurg...
#HPBSky #Surgsky
💉 Gemcitabine + S1 median OS 37 months vs. 26
💡 Is neoadjuvant chemo extending survival over upfront surgery?!
🤔 What are your thoughts?! 💭
journals.lww.com/annalsofsurg...
#HPBSky #Surgsky
A new method for evaluating CA19-9 during neoadjuvant therapy, and its role in predicting overall and disease-free survival in BR-PC. A way towards personalised prognostication! 💜💪🏻🙏🏼
doi.org/10.1097/SLA....
A new method for evaluating CA19-9 during neoadjuvant therapy, and its role in predicting overall and disease-free survival in BR-PC. A way towards personalised prognostication! 💜💪🏻🙏🏼
doi.org/10.1097/SLA....
Progressing with contracts, and looking forward to our Azure platform… soon to be ready 👩🏼💻🧑🏽💻
Stay tuned for updates! 💜🤓
@ammaraj.bsky.social
Progressing with contracts, and looking forward to our Azure platform… soon to be ready 👩🏼💻🧑🏽💻
Stay tuned for updates! 💜🤓
@ammaraj.bsky.social
Join us now! Find the joining questionnaire on pancpals.com/joining-ques...
@ammaraj.bsky.social @marcbesselink.bsky.social
Join us now! Find the joining questionnaire on pancpals.com/joining-ques...
@ammaraj.bsky.social @marcbesselink.bsky.social
⚖️ Reappraisal of the actual benefit of extended surveillance between cancer risk🫸 🫷discontinuation
🧬 "Less invasive" biomarkers are expected to exclude from FU harmless cyst since first observation
🟠 gut.bmj.com/content/earl...
⚖️ Reappraisal of the actual benefit of extended surveillance between cancer risk🫸 🫷discontinuation
🧬 "Less invasive" biomarkers are expected to exclude from FU harmless cyst since first observation
🟠 gut.bmj.com/content/earl...
Followed by an excellent expert panel discussion. 💪🏻 🩺
Thanks everyone!
#AHPBA2025 #PANCPALS 💜
Followed by an excellent expert panel discussion. 💪🏻 🩺
Thanks everyone!
#AHPBA2025 #PANCPALS 💜
🇮🇹 🇺🇸 🇩🇪 🇰🇷 🇳🇱 🇬🇧 🇸🇬 🇪🇸 analysis of 2k IPMN developing WF/HRS
👴 Age and 🫧 cyst size impact the timing of surveillance
🦘 First prudential control always 6 months… then 🦘🦘 2 years if no WF/HRS
journals.lww.com/annalsofsurg...
#HPBSky #SurgSky
🇮🇹 🇺🇸 🇩🇪 🇰🇷 🇳🇱 🇬🇧 🇸🇬 🇪🇸 analysis of 2k IPMN developing WF/HRS
👴 Age and 🫧 cyst size impact the timing of surveillance
🦘 First prudential control always 6 months… then 🦘🦘 2 years if no WF/HRS
journals.lww.com/annalsofsurg...
#HPBSky #SurgSky
📝222 surgeons, 49 countries, 6 continents
📍Heterogeneity in surgical management➡️particularly when ⬆️ venous involvement
⚠️ Need for research 🔍
@eahpba.bsky.social @ihpba.bsky.social
📝222 surgeons, 49 countries, 6 continents
📍Heterogeneity in surgical management➡️particularly when ⬆️ venous involvement
⚠️ Need for research 🔍
@eahpba.bsky.social @ihpba.bsky.social
2️⃣1️⃣ % overall DGE rate
📹 assessment of technical skills ⬇️ DGE rates (after 35 procedures)
🤔 How do you perform GJ after a robotic PD ?! How do you prevent DGE?! 🫵
journals.lww.com/annalsofsurg...
@marcbesselink.bsky.social #HPBSky
2️⃣1️⃣ % overall DGE rate
📹 assessment of technical skills ⬇️ DGE rates (after 35 procedures)
🤔 How do you perform GJ after a robotic PD ?! How do you prevent DGE?! 🫵
journals.lww.com/annalsofsurg...
@marcbesselink.bsky.social #HPBSky
Come visit us at our booth! #AHPBA #PANCPALS
@ammaraj.bsky.social
Come visit us at our booth! #AHPBA #PANCPALS
@ammaraj.bsky.social
🌎 1k resected only 7% after NAT
👍 BR / LAPC no worse OS after NAT
🧪 CA19.9 indicates “biological” treatment effect
👉https://journals.lww.com/annalsofsurgery/abstract/9900/neoadjuvant_chemotherapy_for_intraductal_papillary.1220.aspx
🌎 1k resected only 7% after NAT
👍 BR / LAPC no worse OS after NAT
🧪 CA19.9 indicates “biological” treatment effect
👉https://journals.lww.com/annalsofsurgery/abstract/9900/neoadjuvant_chemotherapy_for_intraductal_papillary.1220.aspx
Meet Dr. Camila Hidalgo Salinas, founder & a consortium coordinator. Dr. Hidalgo Salinas is a Postdoctoral Research Fellow at #NYULangoneHealth #Surgery
She says that with PANC-PALS "We envision a new era of pancreatic cancer research through global collaboration."
Meet Dr. Camila Hidalgo Salinas, founder & a consortium coordinator. Dr. Hidalgo Salinas is a Postdoctoral Research Fellow at #NYULangoneHealth #Surgery
She says that with PANC-PALS "We envision a new era of pancreatic cancer research through global collaboration."
link.springer.com/article/10.1...
link.springer.com/article/10.1...
✅ Videos from 259 pts robotic HJ: 6.9% B/C BL
✅ OSATS score <21 assoc with BL
✅ The rate of BL was 5.1% for OSATS>21 vs 12.5% for OSATS ≤21
▶️ journals.lww.com/annalsofsurg...
✅ Videos from 259 pts robotic HJ: 6.9% B/C BL
✅ OSATS score <21 assoc with BL
✅ The rate of BL was 5.1% for OSATS>21 vs 12.5% for OSATS ≤21
▶️ journals.lww.com/annalsofsurg...